Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;34(6):415-424.
doi: 10.1097/MCA.0000000000001249. Epub 2023 May 8.

Long-term multimodality imaging follow-up of ST-segment elevation myocardial infarction patients treated with bioresorbable vascular scaffold: advantages and challenges

Erlend Eriksen  1   2 , Omeed Neghabat  3   4 , Terje H Larsen  1   5 , Sahrai Saeed  1 , Øyvind Bleie  1
Affiliations

Long-term multimodality imaging follow-up of ST-segment elevation myocardial infarction patients treated with bioresorbable vascular scaffold: advantages and challenges

Erlend Eriksen et al. Coron Artery Dis. .

Abstract

Background: Multislice computed tomography (MSCT) offers a non-invasive method of imaging bioresorbable scaffolds (BRS).

Objectives: To investigate the advantages and challenges using MSCT in the follow-up after BRS implantation.

Method: The BRS cohort consisting of 31 patients in the 'BRS in STEMI' trial was examined by multimodality imaging and followed long-term. Minimum lumen area (MLA) and average lumen area (ALA) were examined 12 and 36 months after BRS implantation with MSCT. Optical coherence tomography (OCT) at 12 months was used as a reference.

Results: Measured by MSCT, the mean MLA was 0.05 ± 1.32 mm² ( P = 0.85), but ALA was 1.32 (±2.59 mm², P = 0.015) greater than by OCT. ALA and MLA did not change significantly from 12 to 36 months. MSCT identified all cases of restenosis but missed one patient with massive malapposition.

Conclusion: Our data support using MSCT in the follow-up after BRS implantation. Invasive investigation should still be considered for patients with unexplained symptoms.

PubMed Disclaimer

References

    1. Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al.; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016; 375:1242–1252.
    1. Rzeszutko L, Depukat R, Dudek D. Biodegradable vascular scaffold ABSORB BVS - scientific evidence and methods of implantation. Postepy Kardiol Interwencyjnej 2013; 9:22–30.
    1. Ehara M, Kawai M, Surmely JF, Matsubara T, Terashima M, Tsuchikane E, et al. Diagnostic accuracy of coronary in-stent restenosis using 64-slice computed tomography: comparison with invasive coronary angiography. J Am Coll Cardiol 2007; 49:951–959.
    1. Sun Z, Davidson R, Lin CH. Multi-detector row CT angiography in the assessment of coronary in-stent restenosis: a systematic review. Eur J Radiol 2009; 69:489–495.
    1. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013; 6:999–1009.

MeSH terms

LinkOut - more resources